TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30895745

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 19
Study: 29634402

Group type: EXPERIMENTAL
Intervention: Imagining a visual stimulus
Number of subjects: 24

Group type: COMPARATOR
Intervention: Actual visual stimulus exposure
Number of subjects: 24
Study: 24793364

Group type: EXPERIMENTAL
Intervention: Prize-based contingency management (CM)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Traditional CM schedule
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Enhanced CM schedule
Number of subjects: 81
Study: 23107588

Group type: EXPERIMENTAL
Intervention: Hands-on training by student tutors (ST)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hands-on training by expert cardiographer (EC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comparison of improvement between groups
Number of subjects: 30
Study: 19731013

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Anastrozole 1 mg for 8 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study: 17606534

Group type: EXPERIMENTAL
Intervention: Oral, attenuated monovalent G1[P8] human rotavirus vaccine (10^4.7 infectious units)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Oral, attenuated monovalent G1[P8] human rotavirus vaccine (10^5.2 infectious units)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Oral, attenuated monovalent G1[P8] human rotavirus vaccine (10^5.8 infectious units)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study: 16221141

Group type: EXPERIMENTAL
Intervention: Eight image enhancement procedures
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Smoothing, shading correction, delineate and grey‐level normalization
Number of subjects: 25
Study: 12198070

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway ProSeal (PLMA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Laryngeal tube airway (LTA)
Number of subjects: 120
Study: 9990748

Group type: EXPERIMENTAL
Intervention: MPI-DLV
Number of subjects: 733
Study: 7774139

Group type: EXPERIMENTAL
Intervention: Intrapartum antibiotics (group 1)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: White blood cell count (WBC)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Urine GBS LA test
Number of subjects: 219
Study: 2321774

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (100 micrograms in 10 ml normal saline)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Epidural normal saline (10 ml)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epidural catheter with no solution injected
Number of subjects: 50
Study: 7359263

Group type: EXPERIMENTAL
Intervention: 7 mg/kg hydrocortisone intravenously every six hours
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no corticosteroids)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Salbutamol inhalations and intravenous aminophylline therapy (common to both groups)
Number of subjects: 19
Study: 30670044

Group type: EXPERIMENTAL
Intervention: Remote cognitive behaviour therapy (RCBT)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 156
Study: 28644208

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) during therapy sessions (S1, S2, S3) consisting of five upper and/or lower extremity exercises.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (standard therapy alone) during therapy sessions (S1, S2, S3).
Number of subjects: 31
Study: 25682816

Group type: EXPERIMENTAL
Intervention: Menstrual Cup (MC)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Pads/Tampons (Control)
Number of subjects: 110
Study: 23982478

Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells (MSC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (nonrandomized)
Number of subjects: 9
Study: 21187202

Group type: EXPERIMENTAL
Intervention: Body-weight supported treadmill training (BWSTT)
Number of subjects: 6
Study: 18984774

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 9795

Group type: COMPARATOR
Intervention: Control (no fenofibrate)
Number of subjects: 9795
Study: 17929488

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ftorotan
Number of subjects: 0
Study: 15011193

Group type: EXPERIMENTAL
Intervention: Patient-centered advance care planning (PC-ACP) interview for 1 hour
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 27
Study: 11678967

Group type: EXPERIMENTAL
Intervention: 5 mg glibenclamide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9624786

Group type: EXPERIMENTAL
Intervention: Walking to theatre by ward nurse
Number of subjects: 100

Group type: COMPARATOR
Intervention: Taken to theatre on a hospital trolley
Number of subjects: 100
Study: 7942732

Group type: EXPERIMENTAL
Intervention: Intraductal ultrasound (IDUS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Endoscopic retrograde pancreatography (ERP)
Number of subjects: 26
Study: 3146503

Group type: EXPERIMENTAL
Intervention: Spontaneously breathing group (n=50)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Artificially ventilated group (n=48)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Spontaneously breathing group
Number of subjects: 98

Group type: COMPARATOR
Intervention: Artificially ventilated group
Number of subjects: 98
Study: 31895439

Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 2292

Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 2292
Study: 30484987

Group type: EXPERIMENTAL
Intervention: Care Notebook intervention (self-monitoring QOL), completed once daily.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 200
Study: 27876083

Group type: EXPERIMENTAL
Intervention: Endovascular treatment and usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care without endovascular treatment
Number of subjects: 0
Study: 25050340

Group type: EXPERIMENTAL
Intervention: Fosaprepitant 150 mg i.v. (NK1 group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ondansetron 4 mg i.v. (ONS group)
Number of subjects: 64
Study: 22207026

Group type: EXPERIMENTAL
Intervention: Subacromial patient-controlled analgesia (SA-PCA) with 0.5% ropivacaine at a rate of 2 ml/h and a patient-controlled bolus dose of 2 ml.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IV-PCA).
Number of subjects: 60

Group type: COMPARATOR
Intervention: IV-PCA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SA-PCA
Number of subjects: 60
Study: 19633051

Group type: EXPERIMENTAL
Intervention: Chemoendocrine adjuvant therapy without goserelin in premenopausal patients with endocrine-responsive tumors
Number of subjects: 2754

Group type: EXPERIMENTAL
Intervention: Goserelin in patients with tumors showing PVI
Number of subjects: 2754

Group type: EXPERIMENTAL
Intervention: Tamoxifen in all patients in trial IX
Number of subjects: 2754

Group type: EXPERIMENTAL
Intervention: Adequate endocrine adjuvant therapy
Number of subjects: 2754
Study: 18922373

Group type: EXPERIMENTAL
Intervention: Alumina ceramic-on-alumina ceramic bearing couples
Number of subjects: 452

Group type: COMPARATOR
Intervention: Conventional polyethylene-on-metal bearing group
Number of subjects: 452
Study: 16881941

Group type: EXPERIMENTAL
Intervention: Standard depression treatment plus literacy education
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard depression treatment
Number of subjects: 70
Study: 12969359

Group type: EXPERIMENTAL
Intervention: rhBMP-2 coated xenogenic bone substitute mineral
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (xenogenic bone substitute without rhBMP-2)
Number of subjects: 11
Study: 11125655

Group type: EXPERIMENTAL
Intervention: 1 plaintiff
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 2 plaintiffs
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 4 plaintiffs
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 6 plaintiffs
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 10 plaintiffs
Number of subjects: 135
Study: 9196416

Group type: EXPERIMENTAL
Intervention: Blood cardioplegic reperfusion with leucocyte depletion (n = 11)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Blood cardioplegic reperfusion without leucocyte depletion (n = 11)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Leucocyte depleted (n = 11)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Blood cardioplegia (n = 11)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Leucocyte depletion in patients with normal ejection fraction (n = 11)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group for normal ejection fraction (n = 11)
Number of subjects: 44
Study: 8263575

Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Eligible Refusers (no TPN)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Index Group (no TPN)
Number of subjects: 395
Study: 3884152

Group type: EXPERIMENTAL
Intervention: 200 mg/m2/day orally
Number of subjects: 13

Group type: COMPARATOR
Intervention: 100 mg/m2/day iv
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oral VP‐16
Number of subjects: 13
Study: 30232721

Group type: EXPERIMENTAL
Intervention: LI-ESWT
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: PDE5i
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 128

Group type: COMPARATOR
Intervention: LI-ESWT vs Control
Number of subjects: 128
Study: 26783317

Group type: EXPERIMENTAL
Intervention: Lying flat 'head down' position for 48 hours
Number of subjects: 92

Group type: COMPARATOR
Intervention: Sitting up position for 48 hours
Number of subjects: 92
Study: 24392497

Group type: EXPERIMENTAL
Intervention: Anesthetic mouthwash along with oral analgesic post biopsy (Group B)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Anesthetic mouthwash alone (Group C)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No analgesic post biopsy, except when required (Group A)
Number of subjects: 300
Study: 22321518

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Home walking program
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual Care Group (UCG) - Control
Number of subjects: 102
Study: 20188627

Group type: EXPERIMENTAL
Intervention: Motivated group 1 (25 Euro cent reward)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Motivated group 2 (50 Euro cent reward)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no reward)
Number of subjects: 33
Study: 17970786

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC) with cyclophosphamide and thiotepa after six courses of cyclophosphamide, doxorubicin, and 5-fluorouracil followed by tamoxifen.
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard-dose (STD) chemotherapy with six courses of cyclophosphamide, doxorubicin, and 5-fluorouracil followed by tamoxifen.
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard-dose (STD) chemotherapy
Number of subjects: 97
Study: 15997634

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg bid (group 1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg bid + nitrendipine 20 mg qd (group 2)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combined therapy (enalapril + nitrendipine)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Monotherapy (enalapril)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 12808267

Group type: EXPERIMENTAL
Intervention: Exercise group (cycle ergometer training for 3 months)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (inactive sedentary lifestyle)
Number of subjects: 28
Study: 10581136

Group type: EXPERIMENTAL
Intervention: Stent placement
Number of subjects: 143

Group type: COMPARATOR
Intervention: PTCA alone
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Optimal PTCA result
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Stenting required
Number of subjects: 143
Study: 8768019

Group type: EXPERIMENTAL
Intervention: 1% hyperbaric bupivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.5% hyperbaric bupivacaine
Number of subjects: 50
Study: 2054268

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg as enteric coated granules administered alone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Omeprazole 20 mg as enteric coated granules administered after ranitidine 300 mg
Number of subjects: 8
Study: 6336977

Group type: EXPERIMENTAL
Intervention: Transfer Factor (TF)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (surgery only)
Number of subjects: 36
Study: 29778344

Group type: EXPERIMENTAL
Intervention: Usual care with pharmacist intervention (medication reconciliation, medication review, participation in ward rounds)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Usual care with pharmacist intervention
Number of subjects: 460

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 460
Study: 29148019

Group type: EXPERIMENTAL
Intervention: Sutures group (running 4-0 absorbable subcuticular suture, 82 cases)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Staples group (interrupted suture with staples, 83 cases)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Sutures group
Number of subjects: 165

Group type: COMPARATOR
Intervention: Staples group
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Sutures group and Staples group
Number of subjects: 165
Study: 27648957

Group type: EXPERIMENTAL
Intervention: Ordered mesoporous silica formulation of fenofibrate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Marketed product based on micronized fenofibrate
Number of subjects: 12
Study: 24613691

Group type: EXPERIMENTAL
Intervention: PVS‐10200 (low-dose cohort A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: PVS‐10200 (high-dose cohort B)
Number of subjects: 21
Study: 23364035

Group type: EXPERIMENTAL
Intervention: Individualized nutritional education program (two counseling sessions and two telephone sessions over 6 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (nutritional counseling after data collection)
Number of subjects: 40
Study: 20399511

Group type: EXPERIMENTAL
Intervention: Adenoidectomy with tympanostomy (A+T)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Adenoidectomy with myringotomy (A+M)
Number of subjects: 78
Study: 17389731

Group type: EXPERIMENTAL
Intervention: Low serum digoxin concentrations (SDC) (0.5-0.9 ng/mL)
Number of subjects: 2890

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2890

Group type: EXPERIMENTAL
Intervention: High serum digoxin concentrations (SDC) (≥ 1 ng/mL)
Number of subjects: 2890

Group type: EXPERIMENTAL
Intervention: Low-dose digoxin (≤ 0.125 mg/d)
Number of subjects: 2890
Study: 15165120

Group type: EXPERIMENTAL
Intervention: cAMP and cGMP levels in sera and platelets
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: cGMP levels in leucocytes
Number of subjects: 120
Study: 12213693

Group type: EXPERIMENTAL
Intervention: PROSPECT (citalopram and/or IPT)
Number of subjects: 255

Group type: COMPARATOR
Intervention: MTLD-2 (paroxetine and IPT)
Number of subjects: 255
Study: 9690571

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 2000 microg/d
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg or 1000 microg BID
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 7857343

Group type: EXPERIMENTAL
Intervention: Intravenous administration of pidotimod (200 mg in bolus)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral administration of pidotimod at 200, 400, and 800 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of pidotimod at 50, 100, and 200 mg (12 volunteers/group) twice a day for 15 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral administration of pidotimod (800 mg) in different formulations (sachets, vials, tablets)
Number of subjects: 60
Study: 2575335

Group type: EXPERIMENTAL
Intervention: Zinc gluconate (200 mg/day, corresponding to 30 mg zinc metal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31184516

Group type: EXPERIMENTAL
Intervention: Individualized in-hospital exercise training program
Number of subjects: 26
Study: 30630742

Group type: EXPERIMENTAL
Intervention: LCHF diet during Adapt trial
Number of subjects: 23

Group type: COMPARATOR
Intervention: CHO diet during Adapt trial
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: LCHF diet during CHO Restoration trial
Number of subjects: 23

Group type: COMPARATOR
Intervention: CHO diet during CHO Restoration trial
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Post-exercise hepcidin-25 concentrations
Number of subjects: 23
Study: 29100250

Group type: EXPERIMENTAL
Intervention: Gait retraining from rearfoot strike to forefoot strike (8 sessions)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study: 25458411

Group type: EXPERIMENTAL
Intervention: Phoenurse female condom (PFC)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Second-generation Femidom female condom (FC2)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Comparison of PFC and FC2
Number of subjects: 290
Study: 23400965

Group type: EXPERIMENTAL
Intervention: H₂-water (1,000 mL/day for 48 weeks)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (pseudo water for 48 weeks)
Number of subjects: 17
Study: 21512082

Group type: EXPERIMENTAL
Intervention: MR arthrography
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional MRI
Number of subjects: 42
Study: 19999361

Group type: EXPERIMENTAL
Intervention: Vinegar irrigation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical antibiotics
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 40
Study: 16201678

Group type: EXPERIMENTAL
Intervention: Neotenous female partner (increased eye-size)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Mature female partner (decreased eye-size)
Number of subjects: 176
Study: 10494638

Group type: EXPERIMENTAL
Intervention: Pouch reconstruction
Number of subjects: 49

Group type: COMPARATOR
Intervention: Roux‐en‐Y reconstruction
Number of subjects: 49
Study: 8640816

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamin C 100 mg/day, vitamin E 280 mg/day, beta-carotene 25 mg/day) for 20 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (nonsmokers without supplementation)
Number of subjects: 0
Study: 1945724

Group type: EXPERIMENTAL
Intervention: Advertisement with a picture of prior earthquake damage
Number of subjects: 40

Group type: COMPARATOR
Intervention: Advertisement without a picture of prior earthquake damage
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Advertisement with statistics on likelihood of an earthquake
Number of subjects: 40

Group type: COMPARATOR
Intervention: Advertisement without statistics on likelihood of an earthquake
Number of subjects: 40
Study: 6752720

Group type: EXPERIMENTAL
Intervention: Alkylating agents (melphalan and chlorambucil)
Number of subjects: 1399

Group type: COMPARATOR
Intervention: Surgery or radiation or both without alkylating agents
Number of subjects: 1399

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (alkylating agents)
Number of subjects: 1399
Study: 30669181

Group type: EXPERIMENTAL
Intervention: i.v. fluid administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: vasopressor use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: baseline demographics, clinical and laboratory variables
Number of subjects: 0
Study: 30372711

Group type: EXPERIMENTAL
Intervention: Desoximetasone spray 0.25% with twice-daily telephone calls to discuss treatment adherence
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment adherence support (control group)
Number of subjects: 0
Study: 26827913

Group type: EXPERIMENTAL
Intervention: PSX1002-GB 12.5 μg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: PSX1002-GB 25 μg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: PSX1002-GB 50 μg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: PSX1002-GB 100 μg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 24500245

Group type: EXPERIMENTAL
Intervention: SAMe 1,600‐3,200 mg/d
Number of subjects: 189
Study: 22866681

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 5992

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5992

Group type: COMPARATOR
Intervention: Control
Number of subjects: 5992
Study: 19683590

Group type: EXPERIMENTAL
Intervention: Aclidinium 200microg
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Aclidinium 400microg
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Aclidinium (all doses)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Aclidinium 100-400microg
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Aclidinium
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Tiotropium 18microg
Number of subjects: 464
Study: 17686823

Group type: EXPERIMENTAL
Intervention: Factor A (retinol and zinc)
Number of subjects: 29450

Group type: EXPERIMENTAL
Intervention: Factor B (riboflavin and niacin)
Number of subjects: 29450

Group type: EXPERIMENTAL
Intervention: Factor C (ascorbic acid and molybdenum)
Number of subjects: 29450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29450

Group type: EXPERIMENTAL
Intervention: Two factors (unspecified)
Number of subjects: 29450

Group type: EXPERIMENTAL
Intervention: All four factors
Number of subjects: 29450
Study: 15716198

Group type: EXPERIMENTAL
Intervention: Alfuzosin (5 mg twice daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg once daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30